ProQR Therapeutics
PRQR
ProQR Therapeutics (PRQR) earnings history
Most recent quarter
- Fiscal period
- Q3 2025
- Period end
- Sep 30, 2025
- EPS actual
- −$0.12
- EPS estimate
- −$0.12
- EPS surprise
- +0.85%
- Revenue surprise
- −42.86%
- Revenue
- $3.4M
- Revenue estimate
- $5.9M
- Reported
- Nov 6, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2025 | Nov 6, 2025 | −$0.12 | −$0.12 | +0.85% | $3.4M | SEC |
| Q2 2025 | Aug 7, 2025 | −$0.14 | −$0.14 | +0.00% | $4.5M | SEC |
| Q1 2025 | May 8, 2025 | −$0.10 | −$0.11 | −7.77% | $4.9M | SEC |
| Q4 2024 | Mar 13, 2025 | −$0.10 | −$0.09 | +2.92% | $4.2M | SEC |
| Q3 2024 | Nov 7, 2024 | −$0.12 | −$0.11 | +5.68% | $4.3M | SEC |
| Q2 2024 | Aug 8, 2024 | −$0.13 | −$0.03 | +75.97% | $6.8M | SEC |
| Q1 2024 | May 9, 2024 | −$0.12 | −$0.10 | +18.13% | $4.8M | SEC |
| Q4 2023 | Mar 13, 2024 | $0.02 | −$0.08 | −513.37% | $6.8M | SEC |
| Q3 2023 | Nov 7, 2023 | −$0.09 | −$0.07 | +18.32% | $1.4M | SEC |
| Q2 2023 | Aug 3, 2023 | −$0.12 | −$0.11 | +9.83% | $1.3M | SEC |
| Q1 2023 | May 16, 2023 | −$0.13 | −$0.12 | +6.29% | $709,895.55 | SEC |
| Q4 2022 | Mar 29, 2023 | −$0.20 | −$0.17 | +13.23% | $1.4M | SEC |
| Q3 2022 | Nov 9, 2022 | −$0.21 | −$0.33 | −60.89% | $936,908.68 | — |
| Q2 2022 | Aug 4, 2022 | −$0.22 | −$0.22 | +1.70% | $1.1M | — |
| Q1 2022 | May 5, 2022 | −$0.26 | −$0.22 | +15.70% | $1.4M | — |
| Q4 2021 | Feb 24, 2022 | −$0.25 | −$0.30 | −17.82% | $271,656.96 | — |
| Q3 2021 | Nov 4, 2021 | −$0.24 | −$0.25 | −6.92% | $1.0M | — |
| Q2 2021 | Aug 5, 2021 | −$0.25 | −$0.28 | −12.98% | $288,173.84 | — |
| Q1 2021 | May 6, 2021 | −$0.29 | −$0.29 | −2.76% | $117,529.94 | — |
| Q4 2020 | Feb 25, 2021 | −$0.30 | −$0.32 | −6.46% | $300,282.40 | — |
Quarterly revenue
Frequently asked questions
When did ProQR Therapeutics (PRQR) last report earnings?
ProQR Therapeutics last reported on Nov 6, 2025, covering fiscal Q3 2025.
Did PRQR beat earnings estimates?
Yes. ProQR Therapeutics reported EPS of −$0.12 for Q3 2025 against a −$0.12 estimate — a 0.85% beat.
How much revenue did PRQR report last quarter?
ProQR Therapeutics reported $3.4M in revenue for Q3 2025, against a consensus estimate of $5.9M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.